@article {7794,
	title = {Smoldering (asymptomatic) multiple myeloma: Current diagnostic criteria, new predictors of outcome, and follow-up recommendations},
	journal = {Journal of Clinical Oncology},
	volume = {28},
	year = {2010},
	note = {Cited By :68Export Date: 21 February 2017},
	month = {2010},
	pages = {690 - 697},
	abstract = {Purpose: To provide an overview on smoldering (asymptomatic) multiple myeloma (SMM) including current diagnostic criteria, predictors of progression, pattern of progression, and outcome. Design: A comprehensive review of the literature on risk factors for progression, treatment attempts to delay progression and outcome in patients with SMM. Results: The risk factors for progression of SMM include: plasma cell mass including M-protein size and percentage of bone marrow clonal plasma cells (BMPC), abnormal free light chain ratio, proportion of phenotypically abnormal BMPC, immunoparesis, evolution pattern (evolving v nonevolving), and pattern of magnetic resonance imaging abnormalities. Most patients with SMM progress with anemia and/or skeletal involvement. Immediate therapy with cytotoxic agents, such as melphalan/prednisone has not resulted in improved outcome. Patients should not be treated until progressive disease with end-organ damage occurs. Increasing anemia is the most reliable indicator of progression. Conclusion: These recently recognized predictors of outcome may be helpful for better disease monitoring and for investigation of new treatment approaches. Thus, recommendations for follow-up every to 3 to 6 months depending on the risk of progression are suggested, and clinical trials with new noncytotoxic biologically derived agents to delay progression, particularly in high-risk patients, are ongoing. {\textcopyright} 2009 by American Society of Clinical Oncology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-77449085405\&doi=10.1200\%2fJCO.2009.22.2257\&partnerID=40\&md5=638e4898ffe93e107b5833320e3eeb3d},
	author = {Blad{\'e}, J. and Dimopoulos, M. and Rosi{\~n}ol, L. and Rajkumar, S.V. and Kyle, R.A.}
}
